Key result
Trimetazidine has sufficient evidence to support its addition in the treatment of symptomatic patients with stable angina.
Why the study?
Does trimetazidine provide cardioprotective effects in patients with chronic coronary heart disease and heart failure?
Does trimetazidine provide cardioprotective effects in patients with chronic coronary heart disease and heart failure?
This review supports the guideline-recommended use of trimetazidine as an add-on treatment for symptomatic patients with stable angina.
Supports trimetazidine addition for symptomatic stable angina; leaves open its cardioprotective role in heart failure.
Trimetazidine (TMZ) is a metabolic agent used in cardiology for more than 40 years. Several studies assessed the cardioprotective effects of TMZ in patients with chronic coronary heart disease (CHD) as well as in patients with heart failure (HF). In light of the inclusion of TMZ in the current guidelines on the management of stable CHD, we reviewed the published literature on TMZ, focusing mainly its effects on patients with stable angina and HF. According to the published literature, there is sufficient evidence to support the addition of this agent in the treatment of symptomatic patients with stable angina.
No takes yet. Share an insight, caveat, or question.
Tsioufis et al. (2014) conducted a review in Chronic coronary heart disease (CHD) and heart failure (HF). Trimetazidine (TMZ) was evaluated. Trimetazidine has sufficient evidence to support its addition in the treatment of symptomatic patients with stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: